Department of Midwifery, Centre of Postgraduate Medical Education, Warsaw, Poland.
Department of Reproductive Health, Centre of Postgraduate Medical Education, 90 Żelazna St., 01-004, Warsaw, Poland.
BMC Pregnancy Childbirth. 2021 Nov 11;21(1):764. doi: 10.1186/s12884-021-04190-w.
There is not enough data regarding practices and protocols on the dose of oxytocin administrated to women during labour. Empirical evidence indicates that compliance with the guidelines improves the quality of healthcare and reduces adverse effects. The study aimed to evaluate practices of oxytocin provision for labour induction and augmentation in two maternity units in Poland.
The article presents a prospective observational study. Data from 545 (n = 545) labours was collected in two maternity units. First, the total dose (the total amount of oxytocin provided from the beginning in the labour ward until delivery including the III and IV stage of labour) and cumulative dose of oxytocin (the amount of oxytocin given until the birth of the neonate) administered to women during labour was calculated. Then, the relationship between the cumulative dose of oxytocin and short term perinatal outcomes (mode of delivery, use of epidural anaesthesia, Apgar scores, birth weight and postpartum blood loss) was analysed. Finally, the compliance of oxytocin supply during labour with national guidelines in the following five criteria: medium, start dose, escalation rate, interval, the continuation of infusion after established labour was examined.
The average cumulative dose of oxytocin administrated to women before birth was 4402 mU following labour induction and 2366 mU following labour augmentation. The actual administration of oxytocin deviated both from the unit and national guidelines in 93.6% of all observed labours (mainly because of continuation of infusion after established labour). We found no statistically significant correlation between the cumulative dose of oxytocin administered and mode of delivery, immediate postpartum blood loss or Apgar scores. There was no observed effect of cumulative dose oxytocin on short-term perinatal outcomes. The two units participating in the study had similar protocols and did not differ significantly in terms of total oxytocin dose, rates of induction and augmentation - the only observed difference was the mode of delivery.
The study showed no effect of the mean cumulative oxytocin dose on short-term perinatal outcomes and high rate of non-compliance of the practice of oxytocin administration for labour induction and augmentation with the national recommendations. Cooperation between different professional groups of maternity care providers should be considered in building national guidelines for maternity care.. Further studies investigating possible long-term effects of the meant cumulative dose of oxytocin and the reasons for non-compliance of practice with guidelines should be carried out.
关于在分娩期间给予女性催产素剂量的实践和方案,数据不足。经验证据表明,遵守指南可提高医疗保健质量并减少不良影响。本研究旨在评估波兰两个产科单位在催产素引产和催产中的应用实践。
本文介绍了一项前瞻性观察性研究。在两个产科单位共收集了 545 名(n=545)产妇的数据。首先,计算了产妇分娩期间给予催产素的总剂量(从分娩病房开始到分娩结束的总剂量,包括第三和第四产程)和催产素的累积剂量(分娩前给予的催产素剂量)。然后,分析了催产素累积剂量与短期围产期结局(分娩方式、硬膜外麻醉的使用、阿普加评分、出生体重和产后失血)之间的关系。最后,检查了在五个标准下分娩期间给予催产素供应与国家指南的一致性:中剂量、起始剂量、递增率、间隔、建立产程后继续输注。
分娩诱导前,妇女分娩前催产素的平均累积剂量为 4402 mU,分娩后催产素的平均累积剂量为 2366 mU。在所有观察到的分娩中,催产素的实际给药在 93.6%的情况下都偏离了单位和国家指南(主要是因为在建立产程后继续输注)。我们没有发现给予的催产素累积剂量与分娩方式、即时产后出血或阿普加评分之间存在统计学上的显著相关性。没有观察到催产素累积剂量对短期围产期结局有影响。参与研究的两个单位有相似的方案,在催产素总剂量、引产和催产素使用率方面没有显著差异-唯一观察到的差异是分娩方式。
该研究表明,平均累积催产素剂量对短期围产期结局没有影响,并且在引产和催产素应用实践中,不遵守国家建议的情况很高。应考虑不同产科保健提供者专业群体之间的合作,制定国家产科保健指南。应开展进一步的研究,以调查催产素平均累积剂量的可能长期影响以及不遵守实践与指南的原因。